Anthony H V Schapira

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3841031/publications.pdf

Version: 2024-02-01

412 papers	46,755 citations	1799 103 h-index	2078 204 g-index
428 all docs	428 docs citations	428 times ranked	33897 citing authors

#	Article	IF	Citations
1	Sphingolipid changes in Parkinson L444P GBA mutation fibroblasts promote Î±-synuclein aggregation. Brain, 2022, 145, 1038-1051.	7.6	30
2	A multinational consensus on dysphagia in Parkinson's disease: screening, diagnosis and prognostic value. Journal of Neurology, 2022, 269, 1335-1352.	3.6	23
3	Ambroxol reverses tau and Î±-synuclein accumulation in a cholinergic N370S GBA1 mutation model. Human Molecular Genetics, 2022, 31, 2396-2405.	2.9	10
4	Safety, Pharmacokinetics, and Pharmacodynamics of Oral Venglustat in Patients with Parkinsonâ€™s Disease and a GBA Mutation: Results from Part 1 of the Randomized, Double-Blinded, Placebo-Controlled MOVES-PD Trial. Journal of Parkinson's Disease, 2022, 12, 557-570.	2.8	34
5	GBA Variants and Parkinson Disease: Mechanisms and Treatments. Cells, 2022, 11, 1261.	4.1	61
6	Glucocerebrosidase-associated Parkinson disease: Pathogenic mechanisms and potential drug treatments. Neurobiology of Disease, 2022, 166, 105663.	4.4	34
7	Somatic copy number variant mutations in alpha-synuclein and genome-wide in brains of synucleinopathy cases. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, A4.2-A4.	1.9	0
8	Brain Microglial Activation Increased in Glucocerebrosidase (<scp>GBA</scp>) Mutation Carriers without Parkinson's disease. Movement Disorders, 2021, 36, 774-779.	3.9	49
9	<scp>LRRK2</scp> Parkinsonism: Does the Response to Gut Bacteria Mitigate the Neurological Picture?. Movement Disorders, 2021, 36, 71-75.	3.9	4
10	The gut-brain axis and Parkinson disease: clinical and pathogenetic relevance. Annals of Medicine, 2021, 53, 611-625.	3.8	39
11	Intronic Haplotypes in the <scp>GBA</scp> Gene Do Not Predict Age at Diagnosis of Parkinson's Disease. Movement Disorders, 2021, 36, 1456-1460.	3.9	5
12	Exploring the Genotypeâ€“Phenotype Correlation in GBA-Parkinson Disease: Clinical Aspects, Biomarkers, and Potential Modifiers. Frontiers in Neurology, 2021, 12, 694764.	2.4	28
13	Non-motor predictors of 36-month quality of life after subthalamic stimulation in Parkinson disease. Npj Parkinson's Disease, 2021, 7, 48.	5.3	23
14	Consensus on the treatment of dysphagia in Parkinson's disease. Journal of the Neurological Sciences, 2021, 430, 120008.	0.6	23
15	Glucocerebrosidase mutations: A paradigm for neurodegeneration pathways. Free Radical Biology and Medicine, 2021, 175, 42-55.	2.9	12
16	Glucocerebrosidase 1 and leucineâ€rich repeat kinase 2 in Parkinson disease and interplay between the two genes. Journal of Neurochemistry, 2021, 159, 826-839.	3.9	7
17	Combined GCASE/ALPHA-synuclein pattern may identify specific prodomal PD patterns in GBA carriers: A cluster analysis study. Journal of the Neurological Sciences, 2021, 429, 119455.	0.6	0
18	The remote assessment of parkinsonism supporting the ongoing development of interventions in Gaucher disease. Neurodegenerative Disease Management, 2021, 11, 451-458.	2.2	7

#	Article	IF	Citations
19	The PINK1â€"Parkin mitophagy signalling pathway is not functional in peripheral blood mononuclear cells. PLoS ONE, 2021, 16, e0259903.	2.5	8
20	Glucocerebrosidase activity, cathepsin D and monomeric Î±-synuclein interactions in a stem cell derived neuronal model of a PD associated GBA1 mutation. Neurobiology of Disease, 2020, 134, 104620.	4.4	42
21	L444P Gba1 mutation increases formation and spread of Î±-synuclein deposits in mice injected with mouse Î±-synuclein pre-formed fibrils. PLoS ONE, 2020, 15, e0238075.	2.5	20
22	Glucocerebrosidase deficiency promotes release of Î±-synuclein fibrils from cultured neurons. Human Molecular Genetics, 2020, 29, 1716-1728.	2.9	35
23	A pragmatic, personalised approach to treatment initiation in Parkinson's disease. Lancet Neurology, The, 2020, 19, 376-378.	10.2	4
24	Pathogenetic insights into young-onset Parkinson disease. Nature Reviews Neurology, 2020, 16, 245-246.	10.1	4
25	Biofluid Biomarkers in Parkinson's Disease: Clarity Amid Controversy. Movement Disorders, 2020, 35, 1128-1133.	3.9	6
26	Enhancing the Activity of Glucocerebrosidase as a Treatment for Parkinson Disease. CNS Drugs, 2020, 34, 915-923.	5.9	14
27	The biochemical basis of interactions between Glucocerebrosidase and alphaâ€synuclein in GBA1 mutation carriers. Journal of Neurochemistry, 2020, 154, 11-24.	3.9	10
28	Ambroxol for the Treatment of Patients With Parkinson Disease With and Without Glucocerebrosidase Gene Mutations. JAMA Neurology, 2020, 77, 427.	9.0	213
29	Functional assessment of glucocerebrosidase modulator efficacy in primary patient-derived macrophages is essential for drug development and patient stratification. Haematologica, 2020, 105, e206-e209.	3.5	5
30	Title is missing!. , 2020, 15, e0238075.		0
31	Title is missing!. , 2020, 15, e0238075.		0
32	Title is missing!. , 2020, 15, e0238075.		0
33	Title is missing!. , 2020, 15, e0238075.		0
34	Evolution and clustering of prodromal parkinsonian features in GBA1 carriers. Movement Disorders, 2019, 34, 1365-1373.	3.9	33
35	Non-motor outcomes depend on location of neurostimulation in Parkinsonâ€™s disease. Brain, 2019, 142, 3592-3604.	7.6	90
36	Evolution of prodromal parkinsonian features in a cohort ofGBAmutation-positive individuals: a 6-year longitudinal study. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 1091-1097.	1.9	44

#	Article	IF	Citations
37	Ablation of the pro-inflammatory master regulator miR-155 does not mitigate neuroinflammation or neurodegeneration in a vertebrate model of Gaucher's disease. Neurobiology of Disease, 2019, 127, 563-569.	4.4	19
38	Investigation of somatic CNVs in brains of synucleinopathy cases using targeted SNCA analysis and single cell sequencing. Acta Neuropathologica Communications, 2019, 7, 219.	5.2	35
39	Glucocerebrosidase mutations and synucleinopathies: Toward a model of precision medicine. Movement Disorders, 2019, 34, 9-21.	3.9	73
40	Evaluation of the detection of GBA missense mutations and other variants using the Oxford Nanopore MinION. Molecular Genetics & Genomic Medicine, 2019, 7, e564.	1.2	65
41	Glucocerebrosidase and Parkinson Disease: Molecular, Clinical, and Therapeutic Implications. Neuroscientist, 2018, 24, 540-559.	3.5	81
42	The role of glucocerebrosidase in Parkinson disease pathogenesis. FEBS Journal, 2018, 285, 3591-3603.	4.7	99
43	Effects of ambroxol on the autophagy-lysosome pathway and mitochondria in primary cortical neurons. Scientific Reports, 2018, 8, 1385.	3.3	74
44	Chaperone-mediated autophagy as a therapeutic target for Parkinson disease. Expert Opinion on Therapeutic Targets, 2018, 22, 823-832.	3.4	31
45	Somatic copy number gains of Î±-synuclein (SNCA) in Parkinsonâ€™s disease and multiple system atrophy brains. Brain, 2018, 141, 2419-2431.	7.6	63
46	A Human Neural Crest Stem Cell-Derived Dopaminergic Neuronal Model Recapitulates Biochemical Abnormalities in GBA1 Mutation Carriers. Stem Cell Reports, 2017, 8, 728-742.	4.8	57
47	Î±-Synuclein structural features inhibit harmful polyunsaturated fatty acid oxidation, suggesting roles in neuroprotection. Journal of Biological Chemistry, 2017, 292, 6927-6937.	3.4	31
48	Systemic PTEN-Akt1-mTOR pathway activity in patients with normal tension glaucoma and ocular hypertension: A case series. Mitochondrion, 2017, 36, 96-102.	3.4	6
49	Safinamide for the treatment of Parkinsonâ€™s disease. Expert Opinion on Pharmacotherapy, 2017, 18, 937-943.	1.8	11
50	Non-motor features of Parkinson disease. Nature Reviews Neuroscience, 2017, 18, 435-450.	10.2	1,182
51	Oral ambroxol increases brain glucocerebrosidase activity in a nonhuman primate. Synapse, 2017, 71, e21967.	1.2	84
52	Assessment of Safety and Efficacy of Safinamide as a Levodopa Adjunct in Patients With Parkinson Disease and Motor Fluctuations. JAMA Neurology, 2017, 74, 216.	9.0	171
53	Insights into the structural biology of Gaucher disease. Experimental Neurology, 2017, 298, 180-190.	4.1	55
54	Advances and insights into neurological practice 2016â˜17. European Journal of Neurology, 2017, 24, 1425-1434.	3.3	1

#	Article	IF	Citations
55	Nonmotor Symptoms in Experimental Models of Parkinson's Disease. International Review of Neurobiology, 2017, 133, 63-89.	2.0	24
56	DJ-1 is a redox sensitive adapter protein for high molecular weight complexes involved in regulation of catecholamine homeostasis. Human Molecular Genetics, 2017, 26, 4028-4041.	2.9	19
57	What would James Parkinson think? A virtual dialogue on factors influencing the development of Parkinson's disease. Movement Disorders, 2017, 32, 1499-1500.	3.9	0
58	Excessive burden of lysosomal storage disorder gene variants in Parkinsonâ€™s disease. Brain, 2017, 140, 3191-3203.	7.6	323
59	The L444P Gba1 mutation enhances alpha-synuclein induced loss of nigral dopaminergic neurons in mice. Brain, 2017, 140, 2706-2721.	7.6	52
60	Glucocerebrosidase in Parkinson's disease: Insights into pathogenesis and prospects for treatment. Movement Disorders, 2016, 31, 830-835.	3.9	32
61	Autophagic lysosome reformation dysfunction in glucocerebrosidase deficient cells: relevance to Parkinson disease. Human Molecular Genetics, 2016, 25, 3432-3445.	2.9	171
62	The relationship between glucocerebrosidase mutations and Parkinson disease. Journal of Neurochemistry, 2016, 139, 77-90.	3.9	167
63	Advances in neurological research and practice. European Journal of Neurology, 2016, 23, 1685-1693.	3.3	1
64	PINK1 disables the anti-fission machinery to segregate damaged mitochondria for mitophagy. Journal of Cell Biology, 2016, 213, 163-171.	5.2	145
65	Molecular changes in the postmortem parkinsonian brain. Journal of Neurochemistry, 2016, 139, 27-58.	3.9	74
66	The Cytomegalovirus protein pUL37Ã—1 targets mitochondria to mediate neuroprotection. Scientific Reports, 2016, 6, 31373.	3.3	9
67	Ambroxol effects in glucocerebrosidase and Î±â€synuclein transgenic mice. Annals of Neurology, 2016, 80, 766-775.	5.3	143
68	Meclizine-induced enhanced glycolysis is neuroprotective in Parkinson disease cell models. Scientific Reports, 2016, 6, 25344.	3.3	42
69	Parkinson disease-linked GBA mutation effects reversed by molecular chaperones in human cell and fly models. Scientific Reports, 2016, 6, 31380.	3.3	133
70	Mitochondrial and lysosomal biogenesis are activated following <scp>PINK</scp>1/parkinâ€mediated mitophagy. Journal of Neurochemistry, 2016, 136, 388-402.	3.9	184
71	Mitochondrial dysfunction associated with glucocerebrosidase deficiency. Neurobiology of Disease, 2016, 90, 43-50.	4.4	79
72	Caveolinopathy presenting with muscle pain and rhabdomyolysis. Neuromuscular Disorders, 2015, 25, S297.	0.6	0

#	Article	IF	Citations
73	No evidence for substrate accumulation in Parkinson brains with GBA mutations. Movement Disorders, 2015, 30, 1085-1089.	3.9	121
74	Distinct clinical and neuropathological features of G51D SNCA mutation cases compared with SNCA duplication and H50Q mutation. Molecular Neurodegeneration, 2015, 10, 41.	10.8	90
75	Practical recommendations for the process of proposing, planning and writing a neurological management guideline by <scp>EAN</scp> task forces. European Journal of Neurology, 2015, 22, 1505-1510.	3.3	40
76	Neurology in evolution 2014â€“2015. European Journal of Neurology, 2015, 22, 1493-1502.	3.3	1
77	The genetics of Parkinson's disease. British Medical Bulletin, 2015, 114, 39-52.	6.9	68
78	Resistance to the most common optic neuropathy is associated with systemic mitochondrial efficiency. Neurobiology of Disease, 2015, 82, 78-85.	4.4	41
79	The H50Q Mutation Induces a 10-fold Decrease in the Solubility of Î±-Synuclein. Journal of Biological Chemistry, 2015, 290, 2395-2404.	3.4	65
80	The measurement and importance of nonâ€motor symptoms in Parkinson disease. European Journal of Neurology, 2015, 22, 2-3.	3.3	17
81	Evolution of Prodromal Clinical Markers of Parkinson Disease in aGBAMutationâ€“Positive Cohort. JAMA Neurology, 2015, 72, 201.	9.0	180
82	Neurodegenerative diseases in the era of targeted therapeutics: how to handle a tangled issue. Molecular and Cellular Neurosciences, 2015, 66, 1-2.	2.2	6
83	Glucocerebrosidase Gene Mutation and Preclinical Markers of Parkinson Diseaseâ€”Reply. JAMA Neurology, 2015, 72, 724.	9.0	1
84	Clinical prodromes of neurodegeneration in Anderson-Fabry disease. Neurology, 2015, 84, 1454-1464.	1.1	58
85	Glucocerebrosidase and Parkinson disease: Recent advances. Molecular and Cellular Neurosciences, 2015, 66, 37-42.	2.2	184
86	Glucocerebrosidase 1 deficientDanio reriomirror key pathological aspects of human Gaucher disease and provide evidence of early microglial activation preceding alpha-synuclein-independent neuronal cell death. Human Molecular Genetics, 2015, 24, 6640-6652.	2.9	108
87	The Role of Functional Dopamine-Transporter SPECT Imaging in Parkinsonian Syndromes, Part 1. American Journal of Neuroradiology, 2015, 36, 229-235.	2.4	68
88	The Role of Functional Dopamine-Transporter SPECT Imaging in Parkinsonian Syndromes, Part 2. American Journal of Neuroradiology, 2015, 36, 236-244.	2.4	49
89	Glycogen storage disease type XV: A case report. Neuromuscular Disorders, 2015, 25, S221.	0.6	1
90	Pathogenic Mechanisms of Neurodegeneration in Parkinson Disease. Neurologic Clinics, 2015, 33, 1-17.	1.8	84

#	Article	IF	Citations
91	Visual short-term memory deficits associated with GBA mutation and Parkinsonâ€™s disease. Brain, 2014, 137, 2303-2311.	7.6	77
92	Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells. Brain, 2014, 137, 1481-1495.	7.6	258
93	Systemic exosomal siRNA delivery reduced alpha-synuclein aggregates in brains of transgenic mice. Movement Disorders, 2014, 29, 1476-1485.	3.9	384
94	Targeting Mitochondria for Neuroprotection in Parkinson Disease. JAMA Neurology, 2014, 71, 537.	9.0	16
95	Early L-dopa, but not pramipexole, restores basal ganglia activity in partially 6-OHDA-lesioned rats. Neurobiology of Disease, 2014, 64, 36-47.	4.4	10
96	Early Versus Delayed Initiation of Pharmacotherapy in Parkinsonâ€™s Disease. Drugs, 2014, 74, 645-657.	10.9	13
97	Mitochondrial impairment increases FL-PINK1 levels by calcium-dependent gene expression. Neurobiology of Disease, 2014, 62, 426-440.	4.4	49
98	Recharging mitochondrial batteries in old eyes. Near infra-red increases ATP. Experimental Eye Research, 2014, 122, 50-53.	2.6	73
99	Slowing of neurodegeneration in Parkinson's disease and Huntington's disease: future therapeutic perspectives. Lancet, The, 2014, 384, 545-555.	13.7	336
100	Patientâ€reported convenience of onceâ€daily versus threeâ€timesâ€daily dosing during longâ€term studies of pramipexole in early and advanced Parkinsonâ€™s disease. European Journal of Neurology, 2013, 20, 50-56.	3.3	22
101	Mitochondria and Quality Control Defects in a Mouse Model of Gaucher Diseaseâ€”Links to Parkinsonâ€™s Disease. Cell Metabolism, 2013, 17, 941-953.	16.2	277
102	Pramipexole Reduces Phosphorylation of Î±-Synuclein at Serine-129. Journal of Molecular Neuroscience, 2013, 51, 573-580.	2.3	14
103	Calcium dysregulation in Parkinsonâ€™s disease. Brain, 2013, 136, 2015-2016.	7.6	50
104	Glucocerebrosidase mutations and the pathogenesis of Parkinson disease. Annals of Medicine, 2013, 45, 511-521.	3.8	107
105	Therapeutic prospects for Parkinson disease. Annals of Neurology, 2013, 74, 337-347.	5.3	122
106	Glucosylceramidase degradation in fibroblasts carrying bi-allelic Parkin mutations. Molecular Genetics and Metabolism, 2013, 109, 402-403.	1.1	5
107	Timing of deep brain stimulation in Parkinson disease: A need for reappraisal?. Annals of Neurology, 2013, 73, 565-575.	5.3	67
108	Î±-Synuclein and Mitochondrial Dysfunction in Parkinsonâ€™s Disease. Molecular Neurobiology, 2013, 47, 587-597.	4.0	120

#	Article	IF	Citations
109	A novel Î±-synuclein missense mutation in Parkinson disease. Neurology, 2013, 80, 1062-1064.	1.1	396
110	Retinal thinning in Gaucher disease patients and carriers: Results of a pilot study. Molecular Genetics and Metabolism, 2013, 109, 221-223.	1.1	28
111	Pramipexole in patients with early Parkinson's disease (PROUD): a randomised delayed-start trial. Lancet Neurology, The, 2013, 12, 747-755.	10.2	175
112	Mitofusin 1 and mitofusin 2 are ubiquitinated in a PINK1/parkin-dependent manner upon induction of mitophagy. Human Molecular Genetics, 2013, 22, 1697-1697.	2.9	4
113	Recent developments in biomarkers in Parkinson disease. Current Opinion in Neurology, 2013, 26, 395-400.	3.6	88
114	A pathway-based analysis provides additional support for an immune-related genetic susceptibility to Parkinson's disease. Human Molecular Genetics, 2013, 22, 1039-1049.	2.9	122
115	Glucocerebrosidase in the pathogenesis and treatment of Parkinson disease. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 3214-3215.	7.1	54
116	A Proposal for a Comprehensive Grading of Parkinson's Disease Severity Combining Motor and Non-Motor Assessments: Meeting an Unmet Need. PLoS ONE, 2013, 8, e57221.	2.5	95
117	Dopaminergic Neuronal Imaging in Genetic Parkinson's Disease: Insights into Pathogenesis. PLoS ONE, 2013, 8, e69190.	2.5	55
118	PRRT2 gene mutations. Neurology, 2012, 79, 2115-2121.	1.1	159
119	G2019S leucine-rich repeat kinase 2 causes uncoupling protein-mediated mitochondrial depolarization. Human Molecular Genetics, 2012, 21, 4201-4213.	2.9	147
120	Efficacy and Safety of Extended- Versus Immediate-Release Pramipexole in Japanese Patients With Advanced and L-dopaâ€“Undertreated Parkinson Disease. Clinical Neuropharmacology, 2012, 35, 174-181.	0.7	30
121	Role of Mitochondria in Parkinsonâ€™s Disease and Huntingtonâ€™s Disease. Oxidative Stress and Disease, 2012, , 415-431.	0.3	0
122	Targeting Mitochondria for Neuroprotection in Parkinson's Disease. Antioxidants and Redox Signaling, 2012, 16, 965-973.	5.4	45
123	Advances in neurology 2011â€“12. European Journal of Neurology, 2012, 19, 1267-1275.	3.3	1
124	Central role and mechanisms of Î²â€cell dysfunction and death in friedreich ataxiaâ€“associated diabetes. Annals of Neurology, 2012, 72, 971-982.	5.3	84
125	Novel pathogenic mutations in the glucocerebrosidase locus. Molecular Genetics and Metabolism, 2012, 106, 495-497.	1.1	5
126	Mitochondrial dysfunction in glaucoma: Understanding genetic influences. Mitochondrion, 2012, 12, 202-212.	3.4	85

#	Article	IF	Citations
127	Glucocerebrosidase deficiency in substantia nigra of parkinson disease brains. Annals of Neurology, 2012, 72, 455-463.	5.3	473
128	Optimizing treatment for Parkinson's disease. European Journal of Neurology, 2012, 19, 1483-1486.	3.3	2
129	Creation of an Open-Access, Mutation-Defined Fibroblast Resource for Neurological Disease Research. PLoS ONE, 2012, 7, e43099.	2.5	44
130	A clinical and family history study of Parkinson's disease in heterozygousglucocerebrosidasemutation carriers. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, 853-854.	1.9	99
131	Mitochondrial diseases. Lancet, The, 2012, 379, 1825-1834.	13.7	411
132	A randomized, doubleâ€blind, placeboâ€controlled trial of safinamide as addâ€on therapy in early Parkinson's disease patients. Movement Disorders, 2012, 27, 106-112.	3.9	106
133	Hyposmia and cognitive impairment in Gaucher disease patients and carriers. Movement Disorders, 2012, 27, 526-532.	3.9	108
134	Monoamine Oxidase B Inhibitors for the Treatment of ParkinsonÊ¼s Disease. CNS Drugs, 2011, 25, 1061-1071.	5.9	111
135	PINK1-parkin-dependent mitophagy involves ubiquitination of mitofusins 1 and 2: Implications for Parkinson disease pathogenesis. Autophagy, 2011, 7, 243-245.	9.1	75
136	Mitochondrial Contribution to Parkinson's Disease Pathogenesis. Parkinson's Disease, 2011, 2011, 1-7.	1.1	95
137	Journal Watch: Our panel of experts highlight the most important research articles across the spectrum of topics relevant to the field of neurodegenerative disease management. Neurodegenerative Disease Management, 2011, 1, 441-443.	2.2	0
138	New LRRK2 variants identified in Parkinsonâ€™s disease. European Journal of Neurology, 2011, 18, 369-370.	3.3	3
139	LRRK2 as a therapeutic target in Parkinsonâ€™s disease. European Journal of Neurology, 2011, 18, 545-546.	3.3	9
140	Publishing changes and information delivery in the clinical neurosciences. European Journal of Neurology, 2011, 18, 1365-1372.	3.3	0
141	Priorities in Parkinson's disease research. Nature Reviews Drug Discovery, 2011, 10, 377-393.	46.4	364
142	Mitochondrial Pathology in Parkinson's Disease. Mount Sinai Journal of Medicine, 2011, 78, 872-881.	1.9	69
143	Aetiopathogenesis of Parkinsonâ€™s disease. Journal of Neurology, 2011, 258, 307-310.	3.6	27
144	PREPARED: Comparison of prolonged and immediate release ropinirole in advanced Parkinson's disease. Movement Disorders, 2011, 26, 1259-1265.	3.9	69

#	Article	IF	Citations
145	Extended-release pramipexole in advanced Parkinson disease. Neurology, 2011, 77, 767-774.	1.1	97
146	Parkinson disease clinical subtypes and their implications. Nature Reviews Neurology, 2011, 7, 247-248.	10.1	16
147	Parkinsonism in patients with chronic hepatitis C treated with interferon-Î±2b: a report of two cases. European Journal of Gastroenterology and Hepatology, 2010, 22, 628-631.	1.6	9
148	Movement disorders: advances in cause and treatment. Lancet Neurology, The, 2010, 9, 6-7.	10.2	11
149	Analysis of the factors influencing the cardiac phenotype in Friedreich's ataxia. Movement Disorders, 2010, 25, 846-852.	3.9	36
150	The nondeclaration of nonmotor symptoms of Parkinson's disease to health care professionals: An international study using the nonmotor symptoms questionnaire. Movement Disorders, 2010, 25, 704-709.	3.9	342
151	Rationale for delayedâ€start study of pramipexole in Parkinson's disease: The PROUD study. Movement Disorders, 2010, 25, 1627-1632.	3.9	38
152	Efficacy, safety, and tolerability of overnight switching from immediateâ€to once daily extendedâ€release pramipexole in early Parkinson's disease. Movement Disorders, 2010, 25, 2326-2332.	3.9	36
153	Randomized, doubleâ€blind, multicenter evaluation of pramipexole extended release once daily in early Parkinson's disease. Movement Disorders, 2010, 25, 2542-2549.	3.9	87
154	Summary of GIGYF2 studies in Parkinsonâ€™s disease: the burden of proof. European Journal of Neurology, 2010, 17, 175-176.	3.3	15
155	Neurology in the European Journal of Neurology. European Journal of Neurology, 2010, 17, 1397-1406.	3.3	0
156	Missing pieces in the Parkinson's disease puzzle. Nature Medicine, 2010, 16, 653-661.	30.7	621
157	Mutant Parkin Impairs Mitochondrial Function and Morphology in Human Fibroblasts. PLoS ONE, 2010, 5, e12962.	2.5	140
158	Mitofusin 1 and mitofusin 2 are ubiquitinated in a PINK1/parkin-dependent manner upon induction of mitophagy. Human Molecular Genetics, 2010, 19, 4861-4870.	2.9	795
159	Chaperone-Mediated Autophagy Markers in Parkinson Disease Brains. Archives of Neurology, 2010, 67, 1464-72.	4.5	440
160	Future Strategies for Neuroprotection in Parkinsonâ€™s Disease. Neurodegenerative Diseases, 2010, 7, 210-212.	1.4	5
161	Safinamide in the treatment of Parkinson's disease. Expert Opinion on Pharmacotherapy, 2010, 11, 2261-2268.	1.8	41
162	Molecular and clinical prodrome of Parkinson disease: implications for treatment. Nature Reviews Neurology, 2010, 6, 309-317.	10.1	166

#	Article	IF	Citations
163	Molecular and clinical pathways to neuroprotection of dopaminergic drugs in Parkinson disease. Neurology, 2009, 72, S44-50.	1.1	58
164	Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment. Lancet Neurology, The, 2009, 8, 464-474.	10.2	1,367
165	Analysis of mutant DNA polymerase Î³ in patients with mitochondrial DNA depletion. Human Mutation, 2009, 30, 248-254.	2.5	52
166	Friedreich's ataxia impact scale: A new measure striving to provide the flexibility required by today's studies. Movement Disorders, 2009, 24, 984-992.	3.9	24
167	Relationship between alpha synuclein phosphorylation, proteasomal inhibition and cell death: relevance to Parkinsonâ€™s disease pathogenesis. Journal of Neurochemistry, 2009, 110, 1005-1013.	3.9	87
168	Early versus delayed initiation of entacapone in levodopaâ€treated patients with Parkinsonâ€™s disease: a longâ€term, retrospective analysis. European Journal of Neurology, 2009, 16, 1305-1311.	3.3	30
169	Perspectives on recent advances in the understanding and treatment of Parkinsonâ€™s disease. European Journal of Neurology, 2009, 16, 1090-1099.	3.3	64
170	Neurobiology and treatment of Parkinson's disease. Trends in Pharmacological Sciences, 2009, 30, 41-47.	8.7	193
171	Characterization of a novel TYMP splice site mutation associated with mitochondrial neurogastrointestinal encephalomyopathy (MNGIE). Neuromuscular Disorders, 2009, 19, 151-154.	0.6	29
172	Protection against paraquat and A53T alpha-synuclein toxicity by cabergoline is partially mediated by dopamine receptors. Journal of the Neurological Sciences, 2009, 278, 44-53.	0.6	17
173	Neuroprotection in Parkinson's disease. Parkinsonism and Related Disorders, 2009, 15, S41-S43.	2.2	23
174	Etiology and Pathogenesis of Parkinson Disease. Neurologic Clinics, 2009, 27, 583-603.	1.8	105
175	Silencing of PINK1 Expression Affects Mitochondrial DNA and Oxidative Phosphorylation in DOPAMINERGIC Cells. PLoS ONE, 2009, 4, e4756.	2.5	173
176	Etiopathogenesis and treatment of Parkinson's disease. Current Topics in Medicinal Chemistry, 2009, 9, 860-8.	2.1	18
177	Mitochondrial Dysfunction in Neurodegenerative Diseases. Neurochemical Research, 2008, 33, 2502-2509.	3.3	65
178	The clinical relevance of levodopa toxicity in the treatment of Parkinson's disease. Movement Disorders, 2008, 23, S515-S520.	3.9	49
179	Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurology, The, 2008, 7, 583-590.	10.2	1,340
180	Dopamine agonists in Parkinsonâ€™s disease. Expert Review of Neurotherapeutics, 2008, 8, 671-677.	2.8	35

#	Article	IF	Citations
181	Uniting Chinese across Asia: the LRRK2 Gly2385Arg risk variant. European Journal of Neurology, 2008, 15, 203-204.	3.3	27
182	Transient Hornerâ€™s syndrome during lumbar epidural anaesthesia. European Journal of Neurology, 2008, 15, 530-531.	3.3	16
183	Hunting for genes in essential tremor. European Journal of Neurology, 2008, 15, 889-890.	3.3	37
184	Mitochondria in the aetiology and pathogenesis of Parkinson's disease. Lancet Neurology, The, 2008, 7, 97-109.	10.2	757
185	Rasagiline in neurodegeneration. Experimental Neurology, 2008, 212, 255-257.	4.1	9
186	Patterns of treatment for restless legs syndrome in primary care in the United Kingdom. Clinical Therapeutics, 2008, 30, 405-418.	2.5	3
187	MITOCHONDRIAL DNA AND DISEASE. CONTINUUM Lifelong Learning in Neurology, 2008, 14, 133-148.	0.8	0
188	Drug selection and timing of initiation of treatment in early Parkinson's disease. Annals of Neurology, 2008, 64, S47-S55.	5.3	29
189	Why have we failed to achieve neuroprotection in Parkinson's disease?. Annals of Neurology, 2008, 64, S101-S110.	5.3	125
190	Treatment Options in the Modern Management of Parkinson Disease. Archives of Neurology, 2007, 64, 1083.	4.5	116
191	Timing the initiation of treatment in Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2007, 79, 615-615.	1.9	6
192	Role of the Pharmacist in the Effective Management of Wearing-Off in Parkinson's Disease. Annals of Pharmacotherapy, 2007, 41, 1842-1849.	1.9	12
193	1.167 PRODEST â€“ Depressive symptoms in Parkinson's disease: Pattern across scales. Parkinsonism and Related Disorders, 2007, 13, S51.	2.2	1
194	2.421 A proteomics and behavioral analysis of the interaction of statins with mitochondrial proteins in a rat model of Parkinson's disease. Parkinsonism and Related Disorders, 2007, 13, S133.	2.2	0
195	2.IS.1. New treatment possibilities with oral Levodopa (Novartis Pharma AG/Orion Corporation). Parkinsonism and Related Disorders, 2007, 13, S144-S145.	2.2	0
196	3.IS.1. Continuous delivery of ropinirole: Improving the management of Parkinson's disease (GlaxoSmithKline). Parkinsonism and Related Disorders, 2007, 13, S190.	2.2	0
197	Mitochondria in the etiology of Parkinson's disease. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2007, 83, 479-491.	1.8	7
198	Clinical correlates of mitochondrial function in Huntington's disease muscle. Movement Disorders, 2007, 22, 1715-1721.	3.9	83

#	Article	IF	Citations
199	Prevalence of nonmotor symptoms in Parkinson's disease in an international setting; Study using nonmotor symptoms questionnaire in 545 patients. Movement Disorders, 2007, 22, 1623-1629.	3.9	461
200	The metric properties of a novel nonâ€motor symptoms scale for Parkinson's disease: Results from an international pilot study. Movement Disorders, 2007, 22, 1901-1911.	3.9	838
201	Future directions in the treatment of Parkinson's disease. Movement Disorders, 2007, 22, S385-S391.	3.9	28
202	Rotigotine transdermal patch in early Parkinson's disease: A randomized, doubleâ€blind, controlled study versus placebo and ropinirole. Movement Disorders, 2007, 22, 2398-2404.	3.9	214
203	Progress in Parkinsonâ€™s disease. European Journal of Neurology, 2007, 15, 1-1.	3.3	11
204	Relapsing neuropathy in an 18-year-old woman. Lancet Neurology, The, 2007, 6, 192-198.	10.2	4
205	Mitochondrial disease. Lancet, The, 2006, 368, 70-82.	13.7	561
206	Friedreich's Ataxia: From Disease Mechanisms to Therapeutic Interventions. Antioxidants and Redox Signaling, 2006, 8, 438-443.	5.4	71
207	End-of-dose Wearing Off in Parkinson Disease. Clinical Neuropharmacology, 2006, 29, 312-321.	0.7	78
208	Novel pharmacological targets for the treatment of Parkinson's disease. Nature Reviews Drug Discovery, 2006, 5, 845-854.	46.4	262
209	Non-motor symptoms of Parkinson's disease: diagnosis and management. Lancet Neurology, The, 2006, 5, 235-245.	10.2	2,202
210	TCH346 as a neuroprotective drug in Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurology, The, 2006, 5, 1013-1020.	10.2	167
211	International multicenter pilot study of the first comprehensive selfâ€completed nonmotor symptoms questionnaire for Parkinson's disease: The NMSQuest study. Movement Disorders, 2006, 21, 916-923.	3.9	865
212	Coordinating outcomes measurement in ataxia research: Do some widely used generic rating scales tick the boxes?. Movement Disorders, 2006, 21, 1396-1403.	3.9	24
213	Timing of treatment initiation in Parkinson's disease: A need for reappraisal?. Annals of Neurology, 2006, 59, 559-562.	5.3	178
214	Proteasomal inhibition causes loss of nigral tyrosine hydroxylase neurons. Annals of Neurology, 2006, 60, 253-255.	5.3	86
215	The Importance of LRRK2 Mutations in Parkinson Disease. Archives of Neurology, 2006, 63, 1225.	4.5	36
216	Etiology of Parkinsonâ€™s disease. Neurology, 2006, 66, S10-23.	1.1	179

#	Article	IF	Citations
217	Pramipexole protects against apoptotic cell death by non-dopaminergic mechanisms. Journal of Neurochemistry, 2005, 92, 215-215.	3.9	1
218	Rasagiline. Nature Reviews Drug Discovery, 2005, 4, 625-626.	46.4	24
219	International cooperative ataxia rating scale (ICARS): Appropriate for studies of Friedreich's ataxia?. Movement Disorders, 2005, 20, 1585-1591.	3.9	68
220	Disorders of the mitochondrial respiratory chain. , 2005, , 909-926.		0
221	Antioxidant Treatment of Patients With Friedreich Ataxia. Archives of Neurology, 2005, 62, 621.	4.5	211
222	Assessment of the significance of mitochondrial DNA damage by chemotherapeutic agents. International Journal of Oncology, 2005, 27, 337.	3.3	2
223	Isolation of transcriptomal changes attributable to LHON mutations and the cybridization process. Brain, 2005, 128, 1026-1037.	7.6	44
224	Severe Impairment of Complex Iâ€“Driven Adenosine Triphosphate Synthesis in Leber Hereditary Optic Neuropathy Cybrids. Archives of Neurology, 2005, 62, 730.	4.5	144
225	Analysis of the trinucleotide CAG repeat from the DNA polymerase Î³ gene (POLG) in patients with Parkinson's disease. Neuroscience Letters, 2005, 376, 56-59.	2.1	39
226	Mitochondrial DNA and disease: What happens when things go wrong. Biochemist, 2005, 27, 24-27.	0.5	2
227	Assessment of <I>In Vitro</I> and <I>In Vivo</I> Mitochondrial Function in Friedreich's Ataxia and Huntington's Disease. , 2004, 277, 293-308.		22
228	Diagnosing restless legs syndrome (RLS) in primary care. Current Medical Research and Opinion, 2004, 20, 1785-1795.	1.9	32
229	Measuring the Effects of Therapy in Parkinson Diseaseâ€”Reply. JAMA - Journal of the American Medical Association, 2004, 291, 2430.	7.4	0
230	Neuroprotection in Parkinson Disease. JAMA - Journal of the American Medical Association, 2004, 291, 358.	7.4	258
231	Leber hereditary optic neuropathy mtDNA mutations disrupt glutamate transport in cybrid cell lines. Brain, 2004, 127, 2183-2192.	7.6	106
232	Pramipexole protects against apoptotic cell death by non-dopaminergic mechanisms. Journal of Neurochemistry, 2004, 91, 1075-1081.	3.9	98
233	Disease modification in Parkinson's disease. Lancet Neurology, The, 2004, 3, 362-368.	10.2	65
234	Restless Legs Syndrome. Drugs, 2004, 64, 149-158.	10.9	84

#	Article	IF	Citations
235	Differences in toxicity of the catechol-O-methyl transferase inhibitors, tolcapone and entacapone to cultured human neuroblastoma cells. Neuropharmacology, 2004, 46, 562-569.	4.1	56
236	Excessive daytime sleepiness in Parkinsonâ€™s disease. Neurology, 2004, 63, S24-7.	1.1	36
237	Genetic and environmental factors in the cause of Parkinson's disease. Annals of Neurology, 2003, 53, S16-S25.	5.3	327
238	Rationale for the use of dopamine agonists as neuroprotective agents in Parkinson's disease. Annals of Neurology, 2003, 53, S149-S159.	5.3	51
239	Neuroprotection for Parkinson's disease: Prospects and promises. Annals of Neurology, 2003, 53, S1-S2.	5.3	65
240	Cardiac bioenergetics in Friedreich's ataxia. Annals of Neurology, 2003, 54, 552-552.	5.3	4
241	Leber's Hereditary Optic Neuropathy (LHON) Pathogenic Mutations Induce Mitochondrial-dependent Apoptotic Death in Transmitochondrial Cells Incubated with Galactose Medium. Journal of Biological Chemistry, 2003, 278, 4145-4150.	3.4	169
242	A clinical and genetic study of SPG5A linked autosomal recessive hereditary spastic paraplegia. Neurology, 2003, 61, 235-238.	1.1	32
243	Oxidative Stress and Huntingtonâ€™s Disease. Oxidative Stress and Disease, 2003, , .	0.3	0
244	Progress in Parkinsonâ€™s disease. Neurology, 2003, 61, .	1.1	4
245	Cells Bearing Mutations Causing Leber's Hereditary Optic Neuropathy Are Sensitized to Fas-induced Apoptosis. Journal of Biological Chemistry, 2002, 277, 5810-5815.	3.4	122
246	Genetic and clinical heterogeneity in paroxysmal kinesigenic dyskinesia: Evidence for a third EKD gene. Movement Disorders, 2002, 17, 717-725.	3.9	85
247	Mitochondrial dysfunction associated with neuronal death following status epilepticus in rat. Epilepsy Research, 2002, 48, 157-168.	1.6	96
248	Neuroprotection and dopamine agonists. Neurology, 2002, 58, S9-18.	1.1	75
249	Neuroprotection in Parkinsonâ€™s Disease. Advances in Behavioral Biology, 2002, , 373-378.	0.2	1
250	Nitric oxide enhances MPP+inhibition of complex I. FEBS Letters, 2001, 504, 50-52.	2.8	20
251	Fits and strokes. Lancet, The, 2001, 358, 120.	13.7	8
252	Cardiac energetics are abnormal in Friedreich ataxia patients in the absence of cardiac dysfunction and hypertrophy: An in vivo 31P magnetic resonance spectroscopy study. Cardiovascular Research, 2001, 52, 111-119.	3.8	93

#	Article	IF	Citations
253	Sensitivity of respiratory chain activities to lipid peroxidation: effect of vitamin E deficiency. Biochemical Journal, 2001, 357, 887.	3.7	16
254	Sensitivity of respiratory chain activities to lipid peroxidation: effect of vitamin E deficiency. Biochemical Journal, 2001, 357, 887-892.	3.7	27
255	Updated guidelines for the management of Parkinson's disease. British Journal of Hospital Medicine, 2001, 62, 456-470.	0.2	25
256	Mitochondria and degenerative disorders. American Journal of Medical Genetics Part A, 2001, 106, 27-36.	2.4	244
257	Metabolic enzyme expression in dopaminergic neurons in Parkinson's disease: An in situ hybridization study. Annals of Neurology, 2001, 50, 142-149.	5.3	15
258	A cue to queue for CoQ?. Neurology, 2001, 57, 375-376.	1.1	30
259	Immunological Phenotyping of Fibroblast Cultures from Patients with a Mitochondrial Respiratory Chain Deficit. Laboratory Investigation, 2001, 81, 1069-1077.	3.7	17
260	Mitochondrial Dysfunction in Neurodegenerative Disorders and Ageing. Advances in Experimental Medicine and Biology, 2001, 487, 229-251.	1.6	32
261	Mitochondrial Dysfunction in Friedreichâ€™s Ataxia. NeuroSignals, 2001, 10, 263-270.	0.9	19
262	Antioxidant treatment improves in vivo cardiac and skeletal muscle bioenergetics in patients with Friedreich's ataxia. Annals of Neurology, 2001, 49, 590-6.	5.3	56
263	Causes of neuronal death in Parkinson's disease. Advances in Neurology, 2001, 86, 155-62.	0.8	20
264	Mitochondrial disorders. Current Opinion in Neurology, 2000, 13, 527-532.	3.6	20
265	Waking up to sleep episodes in Parkinson's Disease. Movement Disorders, 2000, 15, 212-215.	3.9	163
266	Sporadic inclusion body myositis not linked to prion protein codon 129 methionine homozygosity. Neurology, 2000, 55, 1235-1235.	1.1	11
267	Cytochrome oxidase immunohistochemistry: clues for genetic mechanisms. Brain, 2000, 123, 591-600.	7.6	42
268	MitBASE : a comprehensive and integrated mitochondrial DNA database. The present status. Nucleic Acids Research, 2000, 28, 148-152.	14.5	18
269	A new family with paroxysmal exercise induced dystonia and migraine: a clinical and genetic study. Journal of Neurology, Neurosurgery and Psychiatry, 2000, 68, 609-614.	1.9	72
270	Expression of mutant alpha-synuclein causes increased susceptibility to dopamine toxicity. Human Molecular Genetics, 2000, 9, 2683-2689.	2.9	182

#	Article	IF	Citations
271	Clinical, biochemical and molecular genetic correlations in Friedreich's ataxia. Human Molecular Genetics, 2000, 9, 275-282.	2.9	312
272	Mitochondrial respiratory chain disorders I: mitochondrial DNA defects. Lancet, The, 2000, 355, 299-304.	13.7	320
273	Mitochondrial respiratory chain disorders II: neurodegenerative disorders and nuclear gene defects. Lancet, The, 2000, 355, 389-394.	13.7	183
274	Continuous dopamine-receptor stimulation in early Parkinson's disease. Trends in Neurosciences, 2000, 23, S117-S126.	8.6	185
275	Sleep attacks (sleep episodes) with pergolide. Lancet, The, 2000, 355, 1332-1333.	13.7	146
276	Oxidative-phosphorylation defects in liver of patients with Wilson's disease. Lancet, The, 2000, 356, 469-474.	13.7	130
277	Mitochondrial dysfunction and free radical damage in the Huntington R6/2 transgenic mouse. Annals of Neurology, 2000, 47, 80-86.	5.3	131
278	The place of COMT inhibitors in the armamentarium of drugs for the treatment of Parkinson's disease. Neurology, 2000, 55, S65-8; discussion S69-71.	1.1	15
279	Secondary abnormalities of mitochondrial DNA associated with neurodegeneration. Biochemical Society Symposia, 1999, 66, 99-110.	2.7	34
280	Science, medicine, and the future: Parkinson's disease. BMJ: British Medical Journal, 1999, 318, 311-314.	2.3	151
281	Deficit of in vivo mitochondrial ATP production in patients with Friedreich ataxia. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 11492-11495.	7.1	337
282	Update of the human MitBASE database. Nucleic Acids Research, 1999, 27, 143-146.	14.5	3
283	MitBASE: a comprehensive and integrated mitochondrial DNA database. Nucleic Acids Research, 1999, 27, 128-133.	14.5	17
284	Mitochondrial myopathies and encephalomyopathies. European Journal of Clinical Investigation, 1999, 29, 886-898.	3.4	36
285	Mitochondrial DNA Mutations and Mitochondrial Dysfunction in Epilepsy. Epilepsia, 1999, 40, 33-40.	5.1	25
286	Biochemical abnormalities and excitotoxicity in Huntington's disease brain. Annals of Neurology, 1999, 45, 25-32.	5.3	439
287	Mitochondria: Aspects for neuroprotection. Drug Development Research, 1999, 46, 57-66.	2.9	0
288	A Missense Mutation of Cytochrome Oxidase Subunit II Causes Defective Assembly and Myopathy. American Journal of Human Genetics, 1999, 65, 1030-1039.	6.2	131

#	Article	IF	Citations
289	Proximal myotonic myopathy (PROMM) presenting as myotonia during pregnancy. Neuromuscular Disorders, 1999, 9, 144-149.	0.6	31
290	Mitochondria in the aetiology and pathogenesis of Parkinson's disease. Parkinsonism and Related Disorders, 1999, 5, 139-143.	2.2	10
291	Clinical, biochemical and molecular genetic features of Leberâ€™s hereditary optic neuropathy. Biochimica Et Biophysica Acta - Bioenergetics, 1999, 1410, 147-158.	1.0	57
292	Mitochondrial involvement in Parkinsonâ€™s disease, Huntingtonâ€™s disease, hereditary spastic paraplegia and Friedreichâ€™s ataxia. Biochimica Et Biophysica Acta - Bioenergetics, 1999, 1410, 159-170.	1.0	271
293	Functional consequences of the 3460-bp mitochondrial DNA mutation associated with Leberâ€™s hereditary optic neuropathy. Journal of the Neurological Sciences, 1999, 165, 10-17.	0.6	64
294	Mitochondrial DNA Depletion Syndrome is Expressed in Amniotic Fluid Cell Cultures. American Journal of Pathology, 1999, 155, 67-70.	3.8	48
295	Mitochondrial DNA in Parkinson's disease. Advances in Neurology, 1999, 80, 233-7.	0.8	3
296	Cyclosporin inhibition of apoptosis induced by mitochondrial complex I toxins. Brain Research, 1998, 809, 12-17.	2.2	102
297	Mitochondrial DNA transmission of the mitochondrial defect in Parkinson's disease. Annals of Neurology, 1998, 44, 177-186.	5.3	301
298	The influence of nuclear background on the biochemical expression of 3460 Leber's hereditary optic neuropathy. Annals of Neurology, 1998, 44, 187-193.	5.3	74
299	Mitochondrial DNA in focal dystonia: A cybrid analysis. Annals of Neurology, 1998, 44, 258-261.	5.3	17
300	Human complex I defects in neurodegenerative diseases. Biochimica Et Biophysica Acta - Bioenergetics, 1998, 1364, 261-270.	1.0	145
301	Mitochondrial dysfunction in neurodegenerative disorders. Biochimica Et Biophysica Acta - Bioenergetics, 1998, 1366, 225-233.	1.0	178
302	Liver failure associated with mitochondrial DNA depletion. Journal of Hepatology, 1998, 28, 556-563.	3.7	106
303	Cytochrome c Oxidase Deficiency Associated with the First Stop-Codon Point Mutation in Human mtDNA. American Journal of Human Genetics, 1998, 63, 29-36.	6.2	135
304	Mitochondrial function, GSH and iron in neurodegeneration and Lewy body diseases. Journal of the Neurological Sciences, 1998, 158, 24-29.	0.6	147
305	Salbutamol treatment in a patient with hyperkalaemic periodic paralysis due to a mutation in the skeletal muscle sodium channel gene (SCN4A). Journal of Neurology, Neurosurgery and Psychiatry, 1998, 65, 248-250.	1.9	44
306	The role of the alpha -synuclein gene mutation in patients with sporadic Parkinson's disease in the United Kingdom. Journal of Neurology, Neurosurgery and Psychiatry, 1998, 65, 378-379.	1.9	28

#	Article	IF	Citations
307	Mitochondria in the etiology and pathogenesis of parkinson's disease. Annals of Neurology, 1998, 44, S89-98.	5.3	206
308	Inborn and Induced Defects of Mitochondria. Archives of Neurology, 1998, 55, 1293.	4.5	19
309	Mitochondrial DNA in idiopathic cardiomyopathy. European Heart Journal, 1998, 19, 1725-1729.	2.2	9
310	PRIMARY AND SECONDARY DEFICIENCIES OF THE MITOCHONDRIAL RESPIRATORY CHAIN. Neurologist, 1998, 4, 169-179.	0.7	0
311	Normal in vivo skeletal muscle oxidative metabolism in sporadic inclusion body myositis assessed by 31P-magnetic resonance spectroscopy. Brain, 1998, 121, 2119-2126.	7.6	43
312	Colloidal Gold Staining and Immunodetection in 2D Protein Mapping. Methods in Molecular Biology, 1998, 80, 237-241.	0.9	1
313	Guidelines for the management of Parkinson's disease. The Parkinson's Disease Consensus Working Group. British Journal of Hospital Medicine, 1998, 59, 469-80.	0.2	12
314	Indices of oxidative stress in Parkinsonâ€™s disease, Alzheimerâ€™s disease and dementia with Lewy bodies. Journal of Neural Transmission Supplementum, 1997, 51, 167-173.	0.5	54
315	Neuromyelitis optica (Devic's syndrome): no association with the primary mitochondrial DNA mutations found in Leber hereditary optic neuropathy.. Journal of Neurology, Neurosurgery and Psychiatry, 1997, 62, 85-87.	1.9	18
316	Molecular Mechanisms in Mitochondrial DNA Depletion Syndrome. Human Molecular Genetics, 1997, 6, 935-942.	2.9	121
317	Congenital muscular dystrophy with severe retrocollis and mental retardation: a report of two siblings.. Journal of Neurology, Neurosurgery and Psychiatry, 1997, 62, 279-281.	1.9	4
318	Mitochondrial disorders. Current Opinion in Neurology, 1997, 10, 43-48.	3.6	12
319	Genetic counselling in mitochondrial diseases. Current Opinion in Neurology, 1997, 10, 408-412.	3.6	8
320	Two pregnant women with vomiting and fits. American Journal of Obstetrics and Gynecology, 1997, 177, 1539-1540.	1.3	18
321	Full length article. Brain Research, 1997, 777, 110-118.	2.2	167
322	Mitochondrial disorders: an overview. Journal of Bioenergetics and Biomembranes, 1997, 29, 105-107.	2.3	19
323	Mitochondrial dysfunction in neurodegeneration. Journal of Bioenergetics and Biomembranes, 1997, 29, 175-183.	2.3	59
324	Mitochondrial function in Huntington's disease: Clues for pathogenesis and prospects for treatment. Annals of Neurology, 1997, 41, 141-142.	5.3	29

#	Article	IF	Citations
325	Complex I function in familial and sporadic dystonia. Annals of Neurology, 1997, 41, 556-559.	5.3	78
326	In vivo skeletal muscle mitochondrial function in Leber's hereditary optic neuropathy assessed by31P magnetic resonance spectroscopy. Annals of Neurology, 1997, 42, 573-579.	5.3	91
327	Mitochondrial respiratory chain function in multiple system atrophy. Movement Disorders, 1997, 12, 418-422.	3.9	65
328	Use of general practitioner computerised records to create a population based twin sample: pilot study based on Parkinson's disease. BMJ: British Medical Journal, 1997, 315, 1510-1511.	2.3	1
329	Unexpected findings of study of selegiline have not been treated with caution its authors advised. BMJ: British Medical Journal, 1997, 315, 370-370.	2.3	1
330	Pathogenesis of Parkinson's disease. BailliÃ¨re's Clinical Neurology, 1997, 6, 15-36.	0.2	32
331	HLA class I genotypes in Leber's hereditary optic neuropathy. Journal of the Neurological Sciences, 1996, 135, 173-175.	0.6	7
332	Oxidative Stress and Parkinson's Diseasea. Annals of the New York Academy of Sciences, 1996, 786, 217-223.	3.8	132
333	Detection of Nitrosyl Complexes in Human Substantia Nigra, in Relation to Parkinson's Disease. Biochemical and Biophysical Research Communications, 1996, 228, 298-305.	2.1	58
334	Oxidative stress and mitochondrial dysfunction in neurodegeneration. Current Opinion in Neurology, 1996, 9, 260-264.	3.6	112
335	Mitochondrial defect in Huntington's disease caudate nucleus. Annals of Neurology, 1996, 39, 385-389.	5.3	690
336	Neurotoxicity and the mechanisms of cell death in Parkinson's disease. Advances in Neurology, 1996, 69, 161-5.	0.8	6
337	Respiratory-deficient human fibroblasts exhibiting defective mitochondrial DNA replication. Biochemical Journal, 1995, 305, 817-822.	3.7	33
338	Oxidative stress in Parkinson's disease. Neuropathology and Applied Neurobiology, 1995, 21, 3-9.	3.2	86
339	L-Dihydroxyphenylalanine and complex I deficiency in Parkinson's disease brain. Movement Disorders, 1995, 10, 295-297.	3.9	40
340	Electron Transport Chain Defects in Alzheimer's Disease. Neurology, 1995, 45, 599-600.	1.1	8
341	Nuclear and mitochondrial genetics in Parkinson's disease.. Journal of Medical Genetics, 1995, 32, 411-414.	3.2	26
342	Mitochondrial DNA (mtDNA) diseases: correlation of genotype to phenotype. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 1995, 1271, 135-140.	3.8	74

#	Article	IF	Citations
343	Antibodies to human optic nerve in Leber's hereditary optic neuropathy. Journal of the Neurological Sciences, 1995, 130, 134-138.	0.6	28
344	The 14484 ND6 mtDNA mutation in Leber hereditary optic neuropathy does not affect fibroblast complex I activity. American Journal of Human Genetics, 1995, 57, 1501-2.	6.2	29
345	British neurology: a national focus.. Journal of Neurology, Neurosurgery and Psychiatry, 1994, 57, 1136-1136.	1.9	0
346	Indices of oxidative stress and mitochondrial function in individuals with incidental Lewy body disease. Annals of Neurology, 1994, 35, 38-44.	5.3	333
347	Complex I, Iron, and ferritin in Parkinson's disease substantia nigra. Annals of Neurology, 1994, 36, 876-881.	5.3	229
348	Platelet mitochondrial function in Leber's hereditary optic neuropathy. Journal of the Neurological Sciences, 1994, 122, 80-83.	0.6	76
349	Mitochondrial DNA mutation underlying Leigh's syndrome: Clinical, pathological, biochemical, and genetic studies of a patient presenting with progressive myoclonic epilepsy. Journal of the Neurological Sciences, 1994, 121, 57-65.	0.6	49
350	A 31P magnetic resonance spectroscopy study of mitochondrial function in skeletal muscle of patients with Parkinson's disease. Journal of the Neurological Sciences, 1994, 125, 77-81.	0.6	64
351	HLA class II genotypes in Leber's hereditary optic neuropathy. Journal of the Neurological Sciences, 1994, 126, 193-196.	0.6	11
352	Reversible inhibition of cytochrome c oxidase, the terminal enzyme of the mitochondrial respiratory chain, by nitric oxide. FEBS Letters, 1994, 345, 50-54.	2.8	1,109
353	Inborn and induced defects of the mitochondrial respiratory chain. Biochemical Society Transactions, 1994, 22, 996-1001.	3.4	5
354	Mitochondrial function and neurotoxicity Editorial review. Current Opinion in Neurology, 1994, 7, 531-534.	3.6	10
355	Complex I Inhibitors Induce Doseâ€Dependent Apoptosis in PC12 Cells: Relevance to Parkinson's Disease. Journal of Neurochemistry, 1994, 63, 1987-1990.	3.9	318
356	Evidence for mitochondrial dysfunction in Parkinson's diseaseâ€”a critical appraisal. Movement Disorders, 1994, 9, 125-138.	3.9	199
357	Advances in the understanding of the cause of Parkinson's disease. Journal of the Royal Society of Medicine, 1994, 87, 373-5.	2.0	0
358	Advances in the Understanding of the Cause of Parkinson's Disease. Journal of the Royal Society of Medicine, 1994, 87, 373-375.	2.0	2
359	Successful outcome of progressive multifocal leukoencephalopathy with cytarabine and interferon. Annals of Neurology, 1993, 33, 407-411.	5.3	71
360	Iron induced oxidative stress and mitochondrial dysfunction: relevance to Parkinson's disease. Brain Research, 1993, 627, 349-353.	2.2	74

#	Article	IF	Citations
361	Mitochondrial disorders. Current Opinion in Genetics and Development, 1993, 3, 457-465.	3.3	18
362	Dorsal root ganglion proteins in Friedreich's ataxia. Neuroscience Letters, 1993, 163, 182-184.	2.1	5
363	Mitochondrial function in Alzheimer's disease. Lancet, The, 1993, 341, 969-970.	13.7	31
364	Mitochondrial cytopathies. Current Opinion in Neurobiology, 1993, 3, 760-767.	4.2	9
365	Smoking and mitochondrial function: a model for environmental toxins. QJM - Monthly Journal of the Association of Physicians, 1993, 86, 657-660.	0.5	74
366	Free radicals and mitochondrial dysfunction in Parkinson's disease. Biochemical Society Transactions, 1993, 21, 367-370.	3.4	39
367	Myopathy in vitamin E deficient rats: muscle fibre necrosis associated with disturbances of mitochondrial function. Journal of Anatomy, 1993, 183 (Pt 3), 451-61.	1.5	23
368	Nuclear complementation restores mtDNA levels in cultured cells from a patient with mtDNA depletion. American Journal of Human Genetics, 1993, 53, 663-9.	6.2	95
369	Mitochondrial complex I deficiency in Parkinson's disease. Advances in Neurology, 1993, 60, 288-91.	0.8	44
370	The use of toxins to elucidate neural function and disease. Current Opinion in Neurology and Neurosurgery, 1993, 6, 448-51.	0.4	0
371	Colloidal Gold Staining and Immunodetection in 2-D Protein Mapping. , 1992, 80, 255-260.		1
372	New insights into the cause of Parkinson's disease. Neurology, 1992, 42, 2241-2241.	1.1	275
373	Mitochondrial function in neurodegeneration and ageing. Mutation Research - DNAging, 1992, 275, 133-143.	3.2	54
374	Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinson's disease. Lancet, The, 1992, 339, 1375-1377.	13.7	443
375	One-step immunoaffinity purification of complex I subunits from beef heart mitochondria. Protein Expression and Purification, 1992, 3, 223-227.	1.3	4
376	Analyses of mitochondrial respiratory chain function and mitochondrial DNA deletion in human skeletal muscle: Effect of ageing. Journal of the Neurological Sciences, 1992, 113, 91-98.	0.6	322
377	BRAIN, SKELETAL MUSCLE AND PLATELET HOMOGENATE MITOCHONDRIAL FUNCTION IN PARKINSON'S DISEASE. Brain, 1992, 115, 333-342.	7.6	332
378	Quantitation of a mitochondrial DNA deletion in Parkinson's disease. FEBS Letters, 1992, 299, 218-222.	2.8	79

#	Article	IF	Citations
379	Irreversible Inhibition of Mitochondrial Complex I by 1-Methyl-4-Phenylpyridinium: Evidence for Free Radical Involvement. Journal of Neurochemistry, 1992, 58, 786-789.	3.9	368
380	Platelet mitochondria function in Parkinson's disease. Annals of Neurology, 1992, 32, 782-788.	5.3	337
381	Oxidative stress as a cause of nigral cell death in Parkinson's disease and incidental lewy body disease. Annals of Neurology, 1992, 32, S82-S87.	5.3	475
382	Alterations in levels of iron, ferritin, and other trace metals in neurodegenerative diseases affecting the basal ganglia. Annals of Neurology, 1992, 32, S94-S100.	5.3	263
383	Mitochondrial function in Parkinson's disease. Annals of Neurology, 1992, 32, S116-S124.	5.3	96
384	Human mitochondrial complex I dysfunction. Biochimica Et Biophysica Acta - Bioenergetics, 1992, 1101, 198-203.	1.0	33
385	MPTP and other Parkinson-inducing agents. Current Opinion in Neurology and Neurosurgery, 1992, 5, 396-400.	0.4	5
386	Neurology.. Postgraduate Medical Journal, 1991, 67, 509-531.	1.8	1
387	A MITOCHONDRIAL ENCEPHALOMYOPATHY WITH SPECIFIC DEFICIENCIES OF TWO RESPIRATORY CHAIN POLYPEPTIDES AND A CIRCULATING AUTOANTIBODY TO A MITOCHONDRIAL MATRIX PROTEIN. Brain, 1990, 113, 419-432.	7.6	25
388	Mitochondrial myopathies: clinical defects. Biochemical Society Transactions, 1990, 18, 523-526.	3.4	13
389	Biochemical and molecular aspects of human mitochondrial respiratory chain disorders. Biochemical Society Transactions, 1990, 18, 517-519.	3.4	14
390	Mitochondrial myopathies: genetic defects. Biochemical Society Transactions, 1990, 18, 519-522.	3.4	22
391	Mitochondrial Complex I Deficiency in Parkinson's Disease. Journal of Neurochemistry, 1990, 54, 823-827.	3.9	1,860
392	Anatomic and Disease Specificity of NADH CoQ₁ Reductase (Complex I) Deficiency in Parkinson's Disease. Journal of Neurochemistry, 1990, 55, 2142-2145.	3.9	670
393	A case of mitochondrial myopathy, lactic acidosis and complex I deficiency. Journal of Neurology, 1990, 237, 399-404.	3.6	24
394	Mitochondrial DNA analysis in Parkinson's disease. Movement Disorders, 1990, 5, 294-297.	3.9	112
395	Mitochondrial Myopathy with a Defect of Mitochondrial-Protein Transport. New England Journal of Medicine, 1990, 323, 37-42.	27.0	59
396	Mitochondrial function and parental sex effect in Huntington's disease. Lancet, The, 1990, 336, 749.	13.7	123

#	Article	IF	Citations
397	The molecular pathology of respiratory-chain dysfunction in human mitochondrial myopathies. Biochimica Et Biophysica Acta - Bioenergetics, 1990, 1018, 217-222.	1.0	27
398	Mitochondrial myopathies.. BMJ: British Medical Journal, 1989, 298, 1127-1128.	2.3	11
399	Mitochondrial myopathies: Clinical and biochemical features of 30 patients with major deletions of muscle mitochondrial DNA. Annals of Neurology, 1989, 26, 699-708.	5.3	309
400	Polypeptide and glycoprotein abnormalities in dorsal root ganglia of streptozotocin-diabetic rats. Journal of the Neurological Sciences, 1989, 94, 147-161.	0.6	1
401	MITOCHONDRIAL COMPLEX I DEFICIENCY IN PARKINSON'S DISEASE. Lancet, The, 1989, 333, 1269.	13.7	1,248
402	Two-dimensional protein mapping by gold stain and immunoblotting. Analytical Biochemistry, 1988, 169, 167-171.	2.4	17
403	Molecular defects of NADH-ubiquinone oxidoreductase (Complex I) in mitochondrial diseases. Journal of Bioenergetics and Biomembranes, 1988, 20, 365-382.	2.3	72
404	MOLECULAR BASIS OF MITOCHONDRIAL MYOPATHIES: POLYPEPTIDE ANALYSIS IN COMPLEX-1 DEFICIENCY. Lancet, The, 1988, 331, 500-503.	13.7	66
405	The mitochondrial myopathies. Defects of the mitochondrial respiratory chain and oxidative phosphorylation system. Electroencephalography and Clinical Neurophysiology Supplement, 1987, 39, 103-14.	0.0	1
406	Pseudomonas osteitis causing cranial nerve palsies.. Journal of Neurology, Neurosurgery and Psychiatry, 1985, 48, 1306-1307.	1.9	1
407	Platelet aggregation in myotonia. Journal of the Neurological Sciences, 1985, 71, 351-357.	0.6	7
408	HOW DOES LIGNOCAINE PREVENT VENTRICULAR FIBRILLATION?. Lancet, The, 1981, 318, 1167-1168.	13.7	0
409	Anaesthetics increase light emission from aequorin at constant ionised calcium. Nature, 1980, 284, 168-169.	27.8	42
410	VANCOMYCIN DOSE FOR PSEUDOMEMBRANOUS COLITIS. Lancet, The, 1980, 316, 204.	13.7	7
411	What is Parkinson's Disease? From Pathophysiology to Symptoms. , 0, , 1-39.		3
412	Treatment of Parkinson's Disease. , 0, , 40-62.		0